Bach P. Monthly and median costs of cancer drugs at the time of FDA approval 1965-2015. Memorial Sloan Kettering Cancer Center. Accessed December 9, 2015. Available at: https://www.mskcc.org/research-areas/programs-centers/health-policy-outcomes/cost-drugs
Dusetzina SB, Huskamp HA, Keating NL. Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019. JAMA 2019;321:2025–2028.
Alevizakos M, Gaitanidis A, Appleman L. Quantification of the financial burden of antineoplastic agent price increases [abstract]. J Clin Oncol 2019;37(Suppl):Abstract 6519.
Howard DH, Bach PB, Berndt ER, . Pricing in the market for anticancer drugs. J Econ Perspect 2015;29:139–162.
Barnes TA, Amir E, Templeton AJ, . Efficacy, safety, tolerability and price of newly approved drugs in solid tumors. Cancer Treat Rev 2017;56:1–7.
Amir E, Seruga B, Martinez-Lopez J, . Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011;29:2543–2549.
Mailankody S, Prasad V. Implications of proposed Medicare reforms to counteract high cancer drug prices. JAMA 2016;316:271–272.
Saluja R, Arciero VS, Cheng S, . Examining trends in cost and clinical benefit of novel anticancer drugs over time. J Oncol Pract 2018;14:e280–294.
Becker DJ, Lin D, Lee S, . Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs. J Oncol Pract 2017;13:e653–665.
Vivot A, Jacot J, Zeitoun JD, . Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. Ann Oncol 2017;28:1111–1116.
Del Paggio JC, Sullivan R, Schrag D, . Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol 2017;18:887–894.
Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015;1:539–540.
Soriot P. Statement of Pascal Soriot, chief executive officer, AstraZeneca, before the Committee on Finance, United States Senate, concerning drug pricing in America: a prescription for change, part II. Accessed September 27, 2019. Available at: https://www.finance.senate.gov/imo/media/doc/26FEB2019SORIOT-ASTRAZENECA.pdf
Harris G. Cost of developing new medicine swelled to $802 million, research study reports. The Wall Street Journal. December 3, 2001. Accessed September 27, 2019. Available at: https://www.wsj.com/articles/SB1007336440403996240
Shah-Manek B, Wong W, Ravelo A, . Oncologists’ perceptions of drug affordability using NCCN Evidence Blocks: results from a national survey. J Manag Care Spec Pharm 2018;24:565–571.
Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626–633.